Reagentia en instrumenten voor immunologie, celbiologie en moleculaire biologie.

Isoliquiritigenin [961-29-5]

Afdrukken

Referentie HY-N0102-200mg

Formaat : 200mg

Neem contact op met een lokale distributeur :

Telefoonnummer : +1 850 650 7790

Merk : MedChemExpress

Meer informatie aanvragen

Neem contact op met een lokale distributeur :

Telefoonnummer : +1 850 650 7790

Description

Isoliquiritigenin is an anti-tumor flavonoid from the root of Glycyrrhiza uralensis Fisch., which inhibits aldose reductase with an IC₅₀ of 320 nM. Isoliquiritigenin is a potent inhibitor of influenza virus replication with an EC₅₀ of 24.7 μM.

IC₅₀ & Target

IC50: 320 nM (Aldose reductase)

Cellular Effect

Cell Line	Type	Value	Description	References
3T3-L1	IC₅₀	96.4 μM Compound: 10	Antiadipogenic activity against mouse 3T3L1 cells assessed as inhibition of differentiation after 7 days by oil-red O staining Antiadipogenic activity against mouse 3T3L1 cells assessed as inhibition of differentiation after 7 days by oil-red O staining	[PMID: 19757853]
A549	IC₅₀	> 20 μM Compound: 3	Inhibition of TNFalpha induced NF-kappaB activation in human A549 cells by luciferase reporter gene assay Inhibition of TNFalpha induced NF-kappaB activation in human A549 cells by luciferase reporter gene assay	[PMID: 19883086]
A549	IC₅₀	52.58 μM Compound: ISL	Antiproliferation activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferation activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 34186178]
A549	IC₅₀	85 μM Compound: 20	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21696954]
A549	GI₅₀	87 μM Compound: 11	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 32345458]
A549	IC₅₀	98.9 μM Compound: 28	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 18440233]
B16-BL6	IC₅₀	80.5 μM Compound: 28	Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 18440233]
BV-2	IC₅₀	> 100 μM Compound: 8	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay	[PMID: 28911817]
C2C12	IC₅₀	26.34 μg/mL Compound: 11	Cytotoxicity against mouse C2C12 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse C2C12 cells assessed as reduction in cell viability by MTT assay	[PMID: 33412152]
C-33-A	IC₅₀	32.83 μM Compound: 2	Cytotoxicity against human C33A cells assessed as reduction in cell viability after 72 hrs Cytotoxicity against human C33A cells assessed as reduction in cell viability after 72 hrs	[PMID: 31539776]
Ca-Ski	IC₅₀	39.09 μM Compound: 2	Cytotoxicity against human CaSki cells assessed as reduction in cell viability after 72 hrs Cytotoxicity against human CaSki cells assessed as reduction in cell viability after 72 hrs	[PMID: 31539776]
CHO	IC₅₀	45.9 μM Compound: 13	Cytotoxicity against CHO cells by MTT assay Cytotoxicity against CHO cells by MTT assay	[PMID: 19572738]
HCT-116	GI₅₀	39 μM Compound: 11	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 32345458]
HEK-293T	IC₅₀	3.42 μg/mL Compound: 6	Inhibition of oseltamivir-resistant H1N1 swine influenza virus neuraminidase H274Y mutant activity expressed in HEK293T cells after 2 hrs by spectrofluorometry Inhibition of oseltamivir-resistant H1N1 swine influenza virus neuraminidase H274Y mutant activity expressed in HEK293T cells after 2 hrs by spectrofluorometry	[PMID: 21123068]
HEK-293T	IC₅₀	3.48 μg/mL Compound: 6	Inhibition of wild type H1N1 swine influenza virus neuraminidase activity expressed in HEK293T cells after 2 hrs by spectrofluorometry Inhibition of wild type H1N1 swine influenza virus neuraminidase activity expressed in HEK293T cells after 2 hrs by spectrofluorometry	[PMID: 21123068]
HeLa	IC₅₀	58.1 μM Compound: 2	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31539776]
HeLa	IC₅₀	58.1 μM Compound: 2	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs	[PMID: 31539776]
HeLa	IC₅₀	82.6 μM Compound: 28	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 18440233]
HepG2	IC₅₀	27.71 μM Compound: ISL	Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 34186178]
HT-1080	IC₅₀	76.7 μM Compound: 28	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 18440233]
Huh-7	CC₅₀	> 50 μM Compound: 24	Cytotoxicity against human Huh7.5.1 cells by MTT assay Cytotoxicity against human Huh7.5.1 cells by MTT assay	[PMID: 22445328]
Huh-7	EC₅₀	36.1 μM Compound: 24	Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay	[PMID: 22445328]
HUVEC	IC₅₀	41.17 μM Compound: Isoliquiritigein	Toxicity against HUVEC incubated for 48 hrs by MTT assay Toxicity against HUVEC incubated for 48 hrs by MTT assay	[PMID: 25590864]
J774.1	IC₅₀	29.3 μM Compound: 16	Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs by Griess reagent assay Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs by Griess reagent assay	[PMID: 15974608]
K562	IC₅₀	29.27 μM Compound: Isoliquiritigein	Antitumor activity against human K562 cells incubated for 48 hrs by MTT assay Antitumor activity against human K562 cells incubated for 48 hrs by MTT assay	[PMID: 25590864]
K562	IC₅₀	32 μM Compound: Isoliquiritigenin	Inhibition of NF-kappaB transactivation in TNF-alpha-stimulated human K562 cells preincubated for 2 hrs followed by TNF-alpha challenge measured after 6 hrs by dual luciferase reporter gene assay Inhibition of NF-kappaB transactivation in TNF-alpha-stimulated human K562 cells preincubated for 2 hrs followed by TNF-alpha challenge measured after 6 hrs by dual luciferase reporter gene assay	[PMID: 24775915]
KB	CC₅₀	12 μM Compound: 10c	Compound concentration required to reduce the exponential growth of KB cells by 50% Compound concentration required to reduce the exponential growth of KB cells by 50%	[PMID: 9767632]
L02	IC₅₀	> 1000 μM Compound: 2	Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31539776]
Lewis lung carcinoma cell line	IC₅₀	84 μM Compound: 28	Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay	[PMID: 18440233]
LoVo	IC₅₀	57 μM Compound: 20	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 21696954]
MCF-10A	IC₅₀	25 μM Compound: Isoliquiritin	Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 to 96 hrs by MTT assay Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 to 96 hrs by MTT assay	[PMID: 33257172]
MCF7	IC₅₀	> 10 μM Compound: Isoliquiritigenin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26690274]
MCF7	GI₅₀	> 100 μM Compound: 11	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32345458]
MCF7	IC₅₀	17.67 μM Compound: ISL	Antiproliferation activity against human MCF-7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferation activity against human MCF-7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 34186178]
MDA-MB-231	IC₅₀	> 10 μM Compound: Isoliquiritigenin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26690274]
MDA-MB-231	IC₅₀	10.86 μM Compound: ISL	Antiproliferation activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferation activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 34186178]
MDA-MB-231	IC₅₀	25 μM Compound: Isoliquiritin	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 to 96 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 to 96 hrs by MTT assay	[PMID: 33257172]
MT4	CC₅₀	7.4 μM Compound: 10c	Compound concentration required to reduce the exponential growth of MT-4 cells by 50% Compound concentration required to reduce the exponential growth of MT-4 cells by 50%	[PMID: 9767632]
NIH3T3	IC₅₀	4.8 μM Compound: 1c	Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay	[PMID: 21112783]
PANC-1	IC₅₀	3.3 μM Compound: 9	Cytotoxicity against human PANC1 cells after 72 hrs by WST8 assay Cytotoxicity against human PANC1 cells after 72 hrs by WST8 assay	[PMID: 28495081]
PC-12	IC₅₀	17.8 μM Compound: 2	Cytotoxicity against rat PC12 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against rat PC12 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31539776]
PC-3	IC₅₀	99 μM Compound: 20	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21696954]
RAW264.7	IC₅₀	3.4 μg/mL Compound: 202	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess reagent based assay	[PMID: 31255927]
RAW264.7	IC₅₀	72 μM Compound: 12	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 23743282]
SiHa	IC₅₀	53.76 μM Compound: 2	Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 72 hrs Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 72 hrs	[PMID: 31539776]
SiHa	IC₅₀	53.8 μM Compound: 2	Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31539776]
SK-MEL-28	IC₅₀	75 μM Compound: 20	Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 21696954]
U-373MG ATCC	IC₅₀	68 μM Compound: 20	Cytotoxicity against human U373 cells after 72 hrs by MTT assay Cytotoxicity against human U373 cells after 72 hrs by MTT assay	[PMID: 21696954]
Vero	IC₅₀	31.25 μg/mL Compound: 30	Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 22169259]
Vero	CC₅₀	463.65 μg/mL Compound: 30	Cytotoxicity against african green monkey Vero cells assessed as cell death after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells assessed as cell death after 72 hrs by MTT assay	[PMID: 22169259]

In Vitro

Isoliquiritigenin may prevent diabetic complications through inhibiting rat lens aldose reductase with IC₅₀=320 nM and sorbitol accumulation in human red blood cells with IC₅₀=2.0 μM^[1]. Isoliquiritigenin (100 μM) markedly inhibits the hypoxia-induced prolonged TPS and TR90 of cardiomyocytes. Isoliquiritigenin significantly triggers AMPK Thr172 phosphorylation as compared with vehicle group. Isoliquiritigenin treatment also induces extracellular signal-regulated kinase (ERK) signaling pathway in the cardiomyocytes. Isoliquiritigenin treatment significantly decreases the intracellular ROS levels of isolated cardiomyocytes during hypoxia/reoxygenation^[3]. Isoliquiritigenin not only downregulates IL-6 expression but also significantly decreases levels of phosphorylated ERK and STAT3 and can inhibit phosphorylation levels of ERK and STAT3 induced by recombinant human IL-6, which are critical signaling proteins in IL-6 signaling regulation networks^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Isoliquiritigenin shows concentration-dependent inhibition of the tonic contraction of mouse jejunum induced by various types of stimulants such as CCh (1 mM), KCl (60 mM) and BaCl₂ (0.3 mM) with IC₅₀ values of 4.96±1.97 mM, 4.03±1.34 mM and 3.70±0.58 mM, respectively^[2]. Isoliquiritigenin exhibits significant anti-tumor activity in MM xenograft models and synergistically enhances the anti-myeloma activity of adriamycin^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Masse moléculaire

256.25

Formule

C₁₅H₁₂O₄

CAS No.

961-29-5

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(C1=CC=C(O)C=C1O)/C=C/C2=CC=C(O)C=C2

Structure Classification

Initial Source

Microorganisms

Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvant et solubilité

In Vitro:

Ethanol : 100 mg/mL (390.24 mM; Need ultrasonic)

DMSO : ≥ 100 mg/mL (390.24 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.9024 mL	19.5122 mL	39.0244 mL
5 mM	0.7805 mL	3.9024 mL	7.8049 mL
10 mM	0.3902 mL	1.9512 mL	3.9024 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (9.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 4

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 5

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 6

Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (9.76 mM); Suspended solution

This protocol yields a suspended solution of ≥ 2.5 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Pureté et documentation

Purity: 98.07%

Fiche technique (274 KB) SDS (393 KB)

COA (245 KB) HNMR (248 KB) RP-HPLC (278 KB) LCMS (93 KB)

Instruction de manipulation (2659 KB)

Références

[1]. Aida K, et al. Isoliquiritigenin: a new aldose reductase inhibitor from glycyrrhizae radix. Planta Med. 1990 Jun;56(3):254-8. [Content Brief]

[2]. Sato Y, et al. Isoliquiritigenin, one of the antispasmodic principles of Glycyrrhiza ularensis roots, acts in the lower part of intestine. Biol Pharm Bull. 2007 Jan;30(1):145-9. [Content Brief]

[3]. Zhang X. Natural antioxidant-isoliquiritigenin ameliorates contractile dysfunction of hypoxic cardiomyocytes via AMPK signaling pathway. Mediators Inflamm. 2013;2013:390890. [Content Brief]

[4]. Chen X, et al. Isoliquiritigenin inhibits the growth of multiple myeloma via blocking IL-6 signaling. J Mol Med (Berl). 2012 Nov;90(11):1311-9. [Content Brief]

[5]. Traboulsi H, et al. The Flavonoid Isoliquiritigenin Reduces Lung Inflammation and Mouse Morbidity during Influenza Virus Infection. Antimicrob Agents Chemother. 2015 Oct;59(10):6317-27. [Content Brief]

Misschien heeft u ook interesse in de volgende producten:

Referentie

Beschrijving

Cond.

Price Bef. VAT

TRC-S699105-10MG

(R)-Sulforaphane [142825-10-3]

10mg

60017-10mg

DIR (DIIC18(7))[100068-60-8]

10MG

HY-13755A-10mg

(R)-Sulforaphane [142825-10-3]

10mg

Isoliquiritigenin [961-29-5]

Referentie HY-N0102-200mg

Neem contact op met een lokale distributeur :

Merk : MedChemExpress

Neem contact op met een lokale distributeur :

Isoliquiritigenin Related Antibodies

Misschien heeft u ook interesse in de volgende producten: